Previous 10 | Next 10 |
ZIOPHARM Oncology ([[ZIOP]] +0.3%) has entered into a consulting agreement with Laurence Cooper, the former CEO of the company.Previously, Ziopharm announced the departure of Dr. Cooper and implied a potential role for him at the company in a scientific advisory capacity to support ...
BOSTON and HOUSTON, April 07, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be presenting a poster at the upcoming American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting...
Ziopharm Oncology (ZIOP) recently held an R&D Day to provide an outlook for the company’s future with the new management team in place, notes John McCamant, a biotech sector specialist and editor of The Medical Technology Stock Letter. For further details see: Ziopharm- Cell ...
Today, we take an in-depth look at a small developmental concern called Ziopharm Oncology for the first time in years. The company has several 'shots on goal' in its pipeline and multiple partnerships. Can it finally get something across the finish line? A full analysis of t...
Shares of Ziopharm Oncology (NASDAQ: ZIOP) had sank 10.2% as of 11:26 a.m. EST on Friday. The drop came after Jefferies downgraded the stock from buy to hold and lowered its one-year price target to $5. There's both good news and bad news with this latest downgrade. Jefferie...
Ziopharm Oncology's (ZIOP) focus on its T-cell receptor therapies (TCRs) under development could transform treatment of solid tumors in the long term, according to Jefferies analyst Chris Howerton.However, given that the company has said it will seek a partner to continue development of an IL...
Seeking Alpha's Catalyst Watch for stocks Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week.Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next ...
Shares of Ziopharm Oncology (NASDAQ: ZIOP) were jumping 10.8% higher as of 11:55 a.m. EST on Friday. The solid gain came after the company provided its fourth-quarter update following the market close on Thursday. Ziopharm announced a net loss in the fourth quarter of $22.8 mill...
Image source: The Motley Fool. Ziopharm Oncology Inc (NASDAQ: ZIOP) Q4 2020 Earnings Call Feb 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Ziopharm Oncology Inc (ZIOP) Q4 2020 Earnings Call Transcript
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: ZIOPHARM Oncology, Inc. 2020 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...